Evaluation of WO2012078210 – development process for the preparation of a DP2 receptor antagonist; Ironwood's first development DP2 antagonist

Author： Norman Peter  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.10, 2012-10, pp. : 1257-1261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 12, 2011-12 ,pp. : 1931-1936

Informa Healthcare

Access to resources Recommend Favorite

DP2 receptor antagonists in development

By Norman Peter  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 947-961

Informa Healthcare

Access to resources Recommend Favorite

Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations

By Yu J.L.   Jackson D.M.   Blackham A.  

European Journal of Pharmacology, Vol. 303, Iss. 3, 1996-05 ,pp. : 187-192

Elsevier

Access to resources Recommend Favorite

Partial agonist effects of BW A868C, a selective DP receptor antagonist, on Cl - secretion in dog tracheal epithelium

By Yu J.L.   Jackson D.M.   Blackham A.   Leff P.  

European Journal of Pharmacology, Vol. 304, Iss. 1, 1996-05 ,pp. : 117-122

Elsevier

Access to resources Recommend Favorite

Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development

By Angiolillo Dominick J   Suryadevara Siva   Capranzano Piera   Bass Theodore A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2893-2900

Informa Healthcare

Access to resources Recommend Favorite